Blueprint Medicines Corporation

Good morning. My name is Kelly and I'll be your conference operator today. At this time, I would like to welcome everyone to the Blueprint Medicine's first quarter 2023 financial results conference call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a Q&A session. If you'd like to ask a question during this time, simply press star followed by the number one on your cell phone keypad. If you'd like to withdraw your question, press star followed by the number two. Please plan to limit yourself to one question. Thank you. Jenna Cohen, please begin.

Thank you and good morning everyone. Welcome to the Blueprint Medicine's first quarter 2023 financial and operating results conference call. This morning we issued a press release which outlines the topics we plan to discuss today. You can access the press release as well as the slides that we'll be reviewing by going to the investor section of our website at www.blueprintmedicines.com. Joining today with prepared remarks are Kate Haviland, Chief Executive Officer, Selena Lee, Chief Commercial Officer, Becker Hughes, Chief Medical Officer, and Mike Lansdell, Chief Financial Officer. Fuad Namuni, President of Research and Development, and Christy Rossi, Chief Operating Officer, are also joining our call and will be available for Q&A. Before we begin, I'd like to remind you that some of the statements made during the call today are forward-looking statements and are subject to a number of risks and uncertainties that may cause our actual results to differ materially, including those described in our reports filed with the SEC. I'll now hand the call over to Kate.

Thanks, Jenna, and good morning, everyone. Last year we introduced our 2027 blueprint a five year growth strategy to achieve what we call precision at scale. What lies at the heart of that vision is our ability to scale our business operations as we execute on commercial launches advance our clinical programs and bring even more innovative compounds into the clinic. Our progress in the first quarter of 2023 has certainly shown that we are driving performance and are poised to deliver tremendous value in the years ahead. First, we delivered strong commercial performance in Q1. We achieved $39.1 million in Avakit net product revenue for the quarter, driven by growth and demand, as well as by strong execution that resulted in favorable dynamics in the proportion of patients on commercial drug. In a moment, Felina will discuss in more detail our continued success in driving Avakit uptake in Advanced SM. Second, we continue to advance our pipeline. We are resuming the Vela trial of Blue 222 after working with the FDA to expeditiously resolve a partial clinical hold within weeks. Our team's fast progress and coordination with the FDA emphasize how well we collaborate with regulatory agencies in the face of an ever-evolving regulatory landscape and the urgency with which we are working to bring our investigational medicines to patients in need. Third, we advanced toward key data inflection points for our best-in-class innovative investigational medicines. We announced that next month at ASCO, we will present dose escalation data across three of our development programs. Becker will share more about what you can expect at ASCO later on the call. Blueprint is distinguished by having a breadth of new product opportunities across our pipeline, and while at the same time, we are heading into a major commercial launch with the expansion of our Avakit label. We are now a couple weeks out from our PDUFA date for Avakit and Indolin SM. Our field teams are in the market delivering on pre-launch activities and are ready to support healthcare providers and patients upon approval. This approval will further solidify Blueprint's leadership in SM. As the cornerstone of our SM franchise, Avakit establishes the bar as both the first and best in class therapy for ISM. enabling our team to accelerate the realization of what we are confident will be a greater than $1.5 billion market opportunity. Now let me turn it over to Felina to discuss our commercial progress with Avakit and the confidence we have in our go-to-market execution.